Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immuno-persistence Study of A Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years

Trial Profile

Immuno-persistence Study of A Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jan 2019

At a glance

  • Drugs Human papillomavirus 16/18 vaccine recombinant bivalent Xiamen Innovax (Primary)
  • Indications Human papillomavirus infections
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 03 Jan 2019 Status changed from active, no longer recruiting to completed.
    • 09 Jan 2018 Status changed from not yet recruiting to active, no longer recruiting.
    • 04 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top